Natural Product-Drug Interaction Research: The Roadmap to Best Practices

天然产物-药物相互作用研究：最佳实践路线图

• 批准号: 9902031
• 负责人: MARY F PAINE
• 金额: $ 15.9万
• 依托单位: WASHINGTON STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9902031
• 关键词: Address; Archives; Clinical; Clinical Management; Clinical assessments; Collaborations; Communication; Communities; Complement; Computer Simulation; Data; Databases; Decision Trees; Drug Interactions; Drug Kinetics; Drug usage; Ensure; Future; Goals; Health; Healthcare; Human; In Vitro; Individual; Informatics; Infrastructure; Investigation; Knowledge; Leadership; Literature; Methods; Names; National Center for Complementary and Alternative Medicine; Natural Product Drug; Natural Products; Natural Products Chemistry; Nature; Online Systems; Pharmaceutical Preparations; Pharmacology; Physiological; Procedures; Process; Quality Control; Research; Research Personnel; Risk; Safety; Sales; Sampling; Series; Source; Structure; Vulnerable Populations; Work; base; clinical risk; clinically relevant; data archive; data warehouse; design; experience; improved; in vivo; innovation; liquid chromatography mass spectrometry; models and simulation; multidisciplinary; novel; operation; perpetrators; pharmacokinetic model; public health relevance; quality assurance; repository; web portal

 DESCRIPTION (provided by applicant): As natural products (NP) sales increase, the risk of adverse NP-drug interactions (NPDIs) increases, yet the pharmacokinetic (PK) elucidation and clinical relevance of putative NPDIs remain elusive. Assessing the risk of NPDIs is more challenging than that of drug-drug interactions (DDIs), often due to relatively scant PK knowledge of individual NP constituents that perpetrate these interactions. The proposed U54 Center will develop a roadmap for NPDI research through a series of well-designed human in vitro and in vivo studies (termed Interaction Projects) on 4-6 priority NPs that pose a potential risk for clinically relevant NPDIs. A repository will be developed for the data generated from the Interaction Projects, and results will be communicated to various target audiences through a public portal. This U54 Center is composed of an accomplished team of investigators, including pharmacokineticists with expertise in NPDIs, complemented by expertise in NP chemistry, DDIs, and health information communication. In collaboration with the Steering Committee, an innovative strategy that combines a mechanistic approach with practical considerations (e.g., popularity of the NPs) will be used to select and prioritize 4-6 NPs for further investigation in te Interaction Projects. Mechanistic aspects include curated clinical NDPI data from the widely used Drug Interaction Database (DIDB) of the Informatics Core, structural alerts, and compelling preliminary clinical and in silico NPDI data. Once selected, the NPs will be entered into a Decision Tree for assessment of NPDI liability and probable significance of interactions with victim drugs. In parallel, the Pharmacology Core will develop detailed Statements of Work for the human in vitro and in vivo studies - while the Analytical Core will source, acquire, and characterize the selected NPs - for the Interaction Projects. Upon completion of each project, the Analytical Core will analyze the PK samples, and the Pharmacology Core will develop physiologically-based PK models for further assessment of the clinical relevance of the Interaction Project results. Throughout these projects, the Informatics Core will create a data repository embedded within a public portal web-based application named, NaPDI app, for Natural Product-Drug Interaction application. The repository, built using the DIDB framework, will allow researchers to access both raw data and summarized results. The U54 Center will also develop and share Best Practices recommended for the conduct of NPDI studies, based on the experience with and results from the Interaction Projects, with the research communities via the public portal. Effective dissemination of the Interaction Project results will be ensured through user experience and brand content studies with target audiences - researchers/practitioners and lay public - to refine the public portal content. The Informatics Core will ensure that the U54 Center's results are archived, organized, analyzed, and well-publicized, allowing for improved design of future NPDI research and ultimately, improved decisions on the optimal management of clinically relevant NPDIs.

 描述（通过应用程序）：自然产物（NP）Armacokinetic（PK）阐明和推定的NPDIS的临床相关性仍然难以捉摸U54中心将开发NPDI研究的路线图，其中一系列精心设计的人体体外和体内研究（称为相互作用项目）在4-6的优先NP上，这些NP构成了潜在相关的NPDIS。 ，结果将通过一个公共门户网站，由调查人员组成，将药代动力学家在NPDIS中具有专业知识，并由NP化学专业知识和健康信息交流。 （例如，NP的受欢迎程度）将用于选择和优先级4-6 NP，以在TE交互项目中进行进一步的离子。 Alets，在临床和NPDI数据中引人入胜。核心核心在体内研究中详细的陈述 - 分析性核心核心，并在每个项目的压缩后表征了S的NPS。基于Willop生理的药理学核心PK模型，用于进一步评估这些项目的临床相关性。使用DIDB框架构建的存储库将允许研究人员访问U54 Central也将开发并共享针对NPDI研究的最佳实践，以实现Anteraction CTION项目的经验来确保艰难的用户实验内容对目标受众的研究 - 公开 - 完善公共门户内容。